New pill provides a meaningful step forward for those fighting a rare and debilitating disease

The FDA has granted approval for a first-of-its-kind oral medication designed to treat dermatomyositis, which is a rare and debilitating autoimmune disease. Clinical trials demonstrated that the new pill provides meaningful improvements in both skin and muscle outcomes for patients fighting the condition. While the drug represents a significant step forward in medical treatment for this specific disease, the trial results also indicated that the medication is not without associated risks for the users.